In a groundbreaking study, researchers from the UK and China have discovered a collection of proteins in frozen blood samples that can potentially predict various forms of dementia over a decade before the disease is diagnosed. Published in the journal Nature Aging, this research is part of an ongoing effort by multiple teams to identify individuals at risk for dementia using a simple blood test. Scientists believe that this advancement could greatly accelerate the development of new treatments.
Currently, brain scans are used to detect abnormal levels of a protein called beta amyloid, which can indicate the future development of Alzheimer's dementia. However, these scans can be expensive and may not be covered by insurance. The new study suggests that blood tests may be developed in the future, making it easier and more cost-effective to predict dementia risk.
Dr. Suzanne Schindler, an Alzheimer's researcher at Washington University in St. Louis, comments on the study's findings, stating that blood tests predicting dementia risk within the next 10 years are likely to be developed. However, individuals at higher risk may struggle with knowing how to respond to these predictions.
Lead researcher Jian-Feng Feng of Fudan University in Shanghai highlights the importance of such tests, especially in aging populations like China's. He mentions that talks are underway regarding potential commercial development of a blood test based on this research.
To conduct the study, researchers at the University of Warwick and Fudan University examined 52,645 blood samples from the UK's Biobank research repository, which were collected between 2006 and 2010 from individuals without signs of dementia at the time. Of these participants, 1,417 eventually developed Alzheimer's disease, vascular dementia, or dementia from other causes. The researchers analyzed protein signatures common among these individuals and identified 1,463 proteins associated with dementia, ranking them based on their predictive capabilities.
The study revealed that individuals with higher levels of proteins GFAP, NEFL, GDF15, and LTBP2 in their blood were consistently more likely to develop Alzheimer's disease, vascular dementia, or dementia from any cause. For instance, those with elevated levels of GFAP had a 2.32 times higher likelihood of developing dementia, which confirms previous findings from smaller studies on the role of this protein in dementia.
It is important to note that the research findings have not yet been independently validated. However, one protein identified in the study, neurofilament light, is already used in clinical settings for diagnosing and monitoring conditions such as multiple sclerosis.
While the study did not include clinically available blood tests for Alzheimer’s disease, it is expected that such tests, if incorporated, may have an even better predictive capacity for dementia development. Currently, these types of tests are being utilized to identify potential candidates for clinical trials of treatments in patients with early-stage or presymptomatic dementia.
The recent approval of drugs such as Eisai and Biogen's Leqembi, which target early-stage or presymptomatic dementia, further emphasizes the potential significance of blood tests in identifying individuals who could benefit from these treatments.
In conclusion, this study marks a significant step forward in predicting dementia risk using blood tests. While more validation is needed, the discovery of protein markers that can indicate dementia development a decade in advance has the potential to revolutionize diagnosis and treatment approaches for this debilitating disease.